The next set of Phase III data in Alzheimer's disease will come next year from therapeutic antibodies against beta amyloid. Safety issues have dogged bapineuzumab from Johnson & Johnson's Janssen Alzheimer Immunotherapy unit and partner Pfizer Inc., but new data suggest vascular complications can be mitigated with lower dosing.

Bapineuzumab hit a speed bump in 2009 when imaging studies in Phase II trials revealed vascular abnormalities collectively termed vasogenic edema in the brains of a small number of patients receiving high doses.